Nimesil (Nimesulide)

Nimesulide works by selectively blocking the cyclo‑oxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins that cause inflammation, pain and fever. This targeted inhibition provides anti‑inflammatory and analgesic effects while sparing COX‑1 activity.

The exact dose of Nimesil is determined by the prescribing clinician based on the patient’s condition, age and response. Typically, an adult may be instructed to take one 100 mg sachet a few times daily for a short‑term period, but the prescriber sets the final regimen.

Safety data for nimesulide during pregnancy and lactation are limited, and the product is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Nimesil, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimesil (nimesulide) is a COX‑2‑selective NSAID, which may offer a lower risk of gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or diclofenac. However, it carries its own safety profile, including rare liver toxicity, and should be chosen based on individual patient risk factors.

Store Nimesil sachets at ambient temperature, preferably below 25 °C, in their original packaging to protect from moisture and direct light. Keep out of reach of children and do not use if the package is damaged or the product appears discoloured.

Nimesil is supplied as oral granules for suspension. The contents of one sachet are mixed with a measured amount of water (usually 50 ml) to form a uniform suspension, which is then taken orally as directed by the prescriber.

Serious adverse events include liver injury (hepatotoxicity), severe allergic reactions such as anaphylaxis or skin eruptions, gastrointestinal ulceration or bleeding, and blood disorders like neutropenia. Patients should seek immediate medical attention if they notice jaundice, rash, severe abdominal pain or unexplained bruising.

Nimesil should be avoided in patients with known hypersensitivity to nimesulide or other NSAIDs, active peptic ulcer disease, severe liver or kidney impairment, uncontrolled heart failure, and in those who are pregnant or breastfeeding unless clearly indicated by a physician.